Cargando…
A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405547/ https://www.ncbi.nlm.nih.gov/pubmed/37554680 http://dx.doi.org/10.4103/JCAS.JCAS_116_22 |
_version_ | 1785085556292583424 |
---|---|
author | Gehlawat, Tarun Karia, Umesh K Shah, Shikha R Vyas, Harshita Ravindra Parghi, Mehul B Doshi, Yashika J Shah, Bela J |
author_facet | Gehlawat, Tarun Karia, Umesh K Shah, Shikha R Vyas, Harshita Ravindra Parghi, Mehul B Doshi, Yashika J Shah, Bela J |
author_sort | Gehlawat, Tarun |
collection | PubMed |
description | BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP), autologous platelet-rich fibrin matrix (PRFM), recombinant human epidermal growth factor (rhEGF), and collagen particles in treating nonhealing leg ulcers. MATERIALS AND METHODS: Open, randomized prospective study was conducted in a single tertiary center over 2 years where after fulfilling the criteria, randomization was done into four groups. Group A: Autologous PRP (double spin, manual method, weekly); Group B: Autologous PRFM (weekly); Group C: rhEGF (daily application); and Group D: Collagen particles (weekly) along with cleansing, debris removal, and wound dressing. Treatment endpoints were complete healing/6 months of treatment, whichever was earlier. Follow-up was done two weekly by clinical assessment, photographs, and measurement of the ulcer area. Epi info 7 software was used for statistical analysis. RESULTS: A total of 48 patients completed the study, 12 in each group, with mean age: 42.37 ± 4.56 years and male-to-female ratio 2.6:1. Underlying etiology was varicosities (43.75%), traumatic (25%), diabetes (22.91%), and leprosy (8.34%). At baseline, all groups were comparable in terms of patient and ulcer characteristics. Complete healing was seen in 79.17% at the end of 12 weeks: 91.67% of patients from Groups A and B each, and 66.67% from Groups C and D each. The mean time to complete healing was 6.9 ± 2.5 weeks, the least in Group B (4.73 ± 2.3 weeks). Differences between excellent (≥75%) ulcer healing across all groups were statistically significant at the end of 8 weeks where Group B showed maximum improvement. No major adverse events were seen. CONCLUSION: PRFM resulted in relatively faster ulcer healing compared with other modalities. |
format | Online Article Text |
id | pubmed-10405547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-104055472023-08-08 A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers Gehlawat, Tarun Karia, Umesh K Shah, Shikha R Vyas, Harshita Ravindra Parghi, Mehul B Doshi, Yashika J Shah, Bela J J Cutan Aesthet Surg Original Article BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP), autologous platelet-rich fibrin matrix (PRFM), recombinant human epidermal growth factor (rhEGF), and collagen particles in treating nonhealing leg ulcers. MATERIALS AND METHODS: Open, randomized prospective study was conducted in a single tertiary center over 2 years where after fulfilling the criteria, randomization was done into four groups. Group A: Autologous PRP (double spin, manual method, weekly); Group B: Autologous PRFM (weekly); Group C: rhEGF (daily application); and Group D: Collagen particles (weekly) along with cleansing, debris removal, and wound dressing. Treatment endpoints were complete healing/6 months of treatment, whichever was earlier. Follow-up was done two weekly by clinical assessment, photographs, and measurement of the ulcer area. Epi info 7 software was used for statistical analysis. RESULTS: A total of 48 patients completed the study, 12 in each group, with mean age: 42.37 ± 4.56 years and male-to-female ratio 2.6:1. Underlying etiology was varicosities (43.75%), traumatic (25%), diabetes (22.91%), and leprosy (8.34%). At baseline, all groups were comparable in terms of patient and ulcer characteristics. Complete healing was seen in 79.17% at the end of 12 weeks: 91.67% of patients from Groups A and B each, and 66.67% from Groups C and D each. The mean time to complete healing was 6.9 ± 2.5 weeks, the least in Group B (4.73 ± 2.3 weeks). Differences between excellent (≥75%) ulcer healing across all groups were statistically significant at the end of 8 weeks where Group B showed maximum improvement. No major adverse events were seen. CONCLUSION: PRFM resulted in relatively faster ulcer healing compared with other modalities. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10405547/ /pubmed/37554680 http://dx.doi.org/10.4103/JCAS.JCAS_116_22 Text en Copyright: © 2023 Journal of Cutaneous and Aesthetic Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Gehlawat, Tarun Karia, Umesh K Shah, Shikha R Vyas, Harshita Ravindra Parghi, Mehul B Doshi, Yashika J Shah, Bela J A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title | A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title_full | A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title_fullStr | A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title_full_unstemmed | A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title_short | A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers |
title_sort | comparative study on therapeutic efficacy of autologous platelet-rich plasma, autologous platelet-rich fibrin matrix, recombinant human epidermal growth factor, and collagen particles in nonhealing leg ulcers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405547/ https://www.ncbi.nlm.nih.gov/pubmed/37554680 http://dx.doi.org/10.4103/JCAS.JCAS_116_22 |
work_keys_str_mv | AT gehlawattarun acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT kariaumeshk acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT shahshikhar acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT vyasharshitaravindra acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT parghimehulb acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT doshiyashikaj acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT shahbelaj acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT gehlawattarun comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT kariaumeshk comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT shahshikhar comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT vyasharshitaravindra comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT parghimehulb comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT doshiyashikaj comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers AT shahbelaj comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers |